Skip to navigation Skip to main content
Oncology Nurse Advisor
  • Cancer Types
    • Cancer Types
      • Brain Cancer
      • Breast Cancer
      • Cervical Cancer
      • Chronic Myeloid Leukemia‎
      • Colorectal Cancer
      • Gastrointestinal Cancer
      • General Oncology
      • Genitourinary Cancer
      • Gynecologic Cancer
      • Head and Neck Cancer
      • Hematologic Cancers
      • Kidney Cancer
      • Leukemia
      • Liver Cancer
      • Lung Cancer
      • Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Myeloproliferative Neoplasms
      • Ovarian Cancer
      • Pancreatic Cancer
      • Prostate Cancer
      • Sarcoma
      • Skin Cancer
  • Hot Topics
    • Hot Topics
      • Advisor Forum
      • Ask a Pharmacist
      • Ask the Experts
      • Communication Challenges
      • Complementary and Alternative Medicine
      • From CancerCare
      • General Medicine
      • Issues in Cancer Survivorship
      • Journal Review
      • Navigation
      • Oncology Nursing
      • Radiation and Your Patient
      • Reflections
      • Side-Effect Management
      • Stat Consult
      • The Patient’s Voice
      • The Total Patient
  • Regimens
  • Resources
    • Resources

      Clinical Tools

      • Clinical Charts
      • Drug Information Database
      • Medical Calculators

      Professional Resources

      • Expert Perspective
      • Decision Support in Medicine
      • Digital Issues
      • Job Board
      • Product Directory
      • Useful Links
  • For Patients
    • For Patients
      • Advocacy
      • Cancer Support Groups
      • Fact Sheets
      • Finding Clinical Trials
  • Conferences
    • Conferences

      Oncology Conferences

      • Conference Coverage

      News Resources

      • Daily Oncology News
      • Web Exclusives
  • ONA Summit
  • News
  • CE
  • Fact Sheets
  • Publishers Alliance
  • Navigation
  • Expert Perspective
  • Slideshows
  • Jobs

Home » Headlines

Publish Date October 1, 2015

Most retinoblastoma survivors have normal psychosocial functioning

  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Reddit
  • Print
  • Share by Email

the Oncology Nurse Advisor take:

Most retinoblastoma survivors do not have poorer psychosocial functioning compared with people without cancer, a recent study published online ahead of print in the Journal of Clinical Oncology has shown.

Although survival rates for patients with retinoblastoma are higher than 95% in the United States, there is limited data about the long-term psychosocial outcomes of these survivors.

For the study, researchers surveyed 470 retinoblastoma survivors diagnosed between 1932 and 1994 and treated in New York. Of those, 53.6% had retinoblastoma in both eyes.

Participants completed a comprehensive questionnaire by mail or telephone to evaluate psychosocial outcomes such as psychological distress, anxiety, depression, fear of cancer recurrence, satisfaction with facial appearance, and post-traumatic stress symptoms.

Results showed that retinoblastoma survivors did not have significantly higher rates of depression, somatization, distress, or anxiety compared with noncancer controls.

Researchers also found that bilateral and unilateral retinoblastoma survivors have similar psychological symptoms.

According to the American Cancer Society, retinoblastoma is a rare disease diagnosed in only approximately 200 to 300 children each year in the United States.

Most retinoblastoma survivors do not have poorer psychosocial functioning compared with people without cancer.

Jennifer S. Ford, Joanne F. Chou, Charles A. Sklar, Kevin C. Oeffinger, Danielle Novetsky Friedman, Mary McCabe, Yuelin Li, Brian P. Marr, David H. Abramson, and Ira J. Dunkel, Memorial Sloan Kettering Cancer Center; Jennifer S. Ford, Charles A. Sklar, David H. Abramson, and Ira J.

READ FULL ARTICLE Curated publisher From Ascopubs

Topics:

Head and Neck Cancer Retinoblastoma
  • Loading...

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next post in Headlines
Genetic testing was associated with lower chemotherapy use in high-risk patients and greater use in

Pegteograstim may be effective for reducing chemotherapy-induced neutropenia

Back to Top
  • Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community online and in print. Daily online exclusives cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers.

  • Resources
    • Editorial Board
    • Subscribe
    • Author Guidelines
    • Permissions
    • Reprints
  • User Center
    • About Us
    • Contact Us
    • Advertise
  • Other Haymarket Medical Websites
    • Cancer Therapy Advisor
    • Clinical Advisor
    • Clinical Pain Advisor
    • Dermatology Advisor
    • Endocrinology Advisor
    • Gastroenterology Advisor
    • Hematology Advisor
    • Infectious Disease Advisor
    • McKnight’s Long Term Care News
    • McKnight’s Senior Living
    • Medical Bag
    • MPR
    • myCME
    • Neurology Advisor
    • Ophthalmology Advisor
    • Optometry Advisor
    • Psychiatry Advisor
    • Pulmonology Advisor
    • Rare Disease Advisor
    • Renal and Urology News
    • Rheumatology Advisor
    • The Cardiology Advisor
  • Copyright © 2022 Haymarket Media, Inc. All Rights Reserved
    This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
    Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.

Loading...
Loading...
Loading...
Loading...